Adverum Biotechnologies Profit Margin

Adverum Biotechnologies's profit margin stands at 4909.64% as of September 2025. That compares with 3619.65% in the prior-year period — up 35.6% year over year. That is above the Healthcare sector average of 21.34%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Adverum Biotechnologies reported 4909.64% in profit margin versus 3619.65% a year earlier — a 35.6% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Adverum Biotechnologies sits higher the Healthcare benchmark (21.34%) with a profit margin of 4909.64%. That is roughly 22911.9% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of 4909.64% for Adverum Biotechnologies means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Adverum Biotechnologies's profit margin evolved across reporting periods, while the comparison chart places ADVM next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.